Therapy for metastatic colorectal carcinoma with a combination of methyl-CCNU, 5-fluorouracil vincristine and streptozotocin (MOF-Strep).
Seventy-seven previously untreated patients with measurable metastatic colorectal carcinoma were treated with a combination of methyl-CCNU, 5-fluorouracil (5-FU), vincristine and streptozotocin (MOF-Strep). The treatment schedule consisted of methyl-CCNU, 30 mg/m2 for 5 consecutive days q 10 weeks; 5-FU, 300 mg/m2 IV for five consecutive days q 5 weeks; vincristine, 1 mg IV q 5 weeks; and streptozotocin, 500 mg/m2 IV weekly. Two (3%) patients achieved complete remission (CR); 22 (29%) patients, a partial remission (PR); and 13 (18%) patients, a minor remission (MR). The median duration of remission was eight months (range, 4-25+months) for patients obtaining CR/PR status, and six months (range, 4-15 months) for MR status. The median survival time was 14 months for patients achieving CR/PR versus seven months for non responders. Comparison with a previous study of MOF at Memorial Sloan-Kettering Cancer Center, showed that the MOF-Strep combination produced a significant (P = 0.004) increase in the number of complete and partial remissions, 32% versus 11%, and in survival, 11 versus 9 months, (P = 0.003), respectively.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012673:Semustine / Q000008:administration & dosage; D013307:Streptomycin / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D012673:Semustine; D014750:Vincristine; D005472:Fluorouracil; D013307:Streptomycin